GlassScriptPhysician profile
Peng J Hou
NPI 1215090907
$740.69
in general payments reported to CMS, 2019-2025
15 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.58 · 2021: $16.64 · 2023: $234 · 2024: $278 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $141.47 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.89 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $97.86 | 2023-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $79.83 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $68.25 | 2023-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $43.66 | 2023-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $40.64 | 2024 | Farxiga |
| Mallinckrodt Hospital Products INC. | $24.54 | 2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $23.94 | 2023 | |
| Glaxosmithkline, LLC. | $23.42 | 2023 | Benlysta |
| Novo Nordisk INC | $22.81 | 2024 | Wegovy |
| Kyowa Kirin, INC. | $19.94 | 2023 | Crysvita |
| Aurinia Pharma U.S., INC. | $18.22 | 2025 | Lupkynis |
| Medtronic, INC. | $16.64 | 2021 | |
| Akebia Therapeutics INC | $16.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peng Hou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.